Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This clinical Trial is proposed to explore whether preconditioning chemotherapy of Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy could benefit NSCLC patients with a better clinical outcome.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jinling Hospital, China
• Treatments: Albumin-Bound Paclitaxel; Cisplatin; Paclitaxel

Criteria

Inclusion Criteria:

1. Primary non small cell lung cancer patients with pathology diagnosis with clinical TNM Classification of Malignant Tumours (TNM) stage (IIIa~IV) can not accept operation or unwilling to operation;

2. 40~70 year old, Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points, estimate survival > 3 months;

3. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count(PLT)≥ 80×109/L; Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value;

4. With more than one scalable lesions;

5. Without any other malignant disease;

6. Patients Voluntary attempt, and informed consent.

Exclusion Criteria:

1. Hypersusceptible to paclitaxel, cisplatin, CIK cells and IL-2;

2. With no scalable lesions;

3. Pregnant or lactating women;

4. Uncontrolled brain metastasis with symptoms or with psychal problems can not describe subjective symptoms;

5. With serious visceral organs failure;

6. Patients with the conditions affect the administration, absorb, distribution, metabolism and excretion of the drugs;

7. History of cardiovascular disease, including congestive heart failure, unstable angina patients, myocardial infarction; Cachexia; or other deadly diseases;

8. Serious uncontrollable infection;

9. At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents); Now or recently will join another experimental clinical study;

10. Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.).